Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation.
clinical trials
drug repurposing
informatics
oncology
pharmacology
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
04
2023
accepted:
05
05
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Historically, the effort by academia and industry to develop new chemical entities into lifesaving drugs has limited success in meeting the demands of today's healthcare. Repurposing drugs that are originally approved by the United States Food and Drug Administration or by regulatory authorities around the globe is an attractive strategy to rapidly develop much-needed therapeutics for oncologic indications that extend from treating cancer to managing treatment-related complications. This review discusses computational approaches to harness existing drugs for new therapeutic use in oncology.
Identifiants
pubmed: 37274281
doi: 10.3389/fonc.2023.1198284
pmc: PMC10233043
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1198284Informations de copyright
Copyright © 2023 Dalwadi, Hunt, Bonnen and Ghebre.
Déclaration de conflit d'intérêts
YG is an inventor on patents, owned by Stanford University and Baylor College of Medicine, that protect the development of proton pump inhibitors PPIs for therapeutic use of new indications including radiation dermatitis. YG and MB are inventors on the patent owned by Baylor College of Medicine. SD is involved in clinical trials that aim to repurpose the PPIs for new indications. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13
pubmed: 26400175
Chem Res Toxicol. 2016 Aug 15;29(8):1225-51
pubmed: 27367298
Signal Transduct Target Ther. 2020 Jul 2;5(1):113
pubmed: 32616710
Curr Res Pharmacol Drug Discov. 2021;2:100042
pubmed: 34870150
Dialogues Clin Neurosci. 2006;8(3):335-44
pubmed: 17117615
Radiat Res. 2019 Nov;192(5):473-482
pubmed: 31415221
Eur J Pharmacol. 2019 Jan 5;842:64-69
pubmed: 30326213
Med Ref Serv Q. 2009 Summer;28(2):154-63
pubmed: 19384716
J Cell Biochem. 2022 Feb;123(2):289-305
pubmed: 34672012
Am J Gastroenterol. 2014 May;109(5):620-3
pubmed: 24796999
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
Nat Rev Drug Discov. 2021 Mar;20(3):200-216
pubmed: 33510482
Nat Rev Drug Discov. 2004 Aug;3(8):711-5
pubmed: 15286737
Health Policy. 2011 Apr;100(1):4-17
pubmed: 21256615
Front Oncol. 2022 Aug 05;12:937166
pubmed: 35992826
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Chem Res Toxicol. 2021 Feb 15;34(2):189-216
pubmed: 33140634
Genes (Basel). 2020 Aug 15;11(8):
pubmed: 32824125
Nat Rev Drug Discov. 2023 Apr;22(4):317-335
pubmed: 36781957
Drug Discov Today. 2016 Oct;21(10):1566-1570
pubmed: 27319291
Drug Discov Today. 2019 Oct;24(10):2076-2085
pubmed: 31238113
Eur J Pharmacol. 2015 Jul 15;759:3-13
pubmed: 25818943
Sci Rep. 2023 Jan 5;13(1):222
pubmed: 36604493